在帕金森病和多个系统缩的帕金森亚型亚型中,Substantia Nigra的独特空间转录组模式
Jung Hwan Shin1, Karoliina Eliisa Ruhno2,3, Chaewon Shin4
1Department of Neurology, Seoul National University Hospital & Seoul National University College of Medicine, 101 Daehak Ro, Jongno-gu, Seoul, 07061, South Korea.
Acta neuropathologica communications
|September 24, 2025
概括
帕金森病 (PD) 和多个系统性缩 (MSA-P) 在黑色物质紧体 (SNpc) 中具有相同的转录基因变化,影响蛋白质合成和线粒体功能,但在免疫反应途径上有所不同.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 帕金森病 (PD) 和帕金森的多系统性缩 (MSA-P) 亚型是神经退行性疾病,影响黑色物质紧体 (SNpc).
- 了解它们独特的转录组特征对于开发有针对性的疗法至关重要.
研究的目的:
- 研究和比较MSA-P和PD患者与健康对照 (HC) 中的SNpc的转录组特征.
- 在每个疾病组中识别差异表达基因 (DEG) 和丰富的途径.
主要方法:
- 在死后的SNPc组织上使用in-situ杂交的转录组分析.
- 来自6名参与者的72个感兴趣区域的分析 (2个MSA-P,2个PD,2个HC).
- 识别DEG和路径丰富分析,包括网络传播.
主要成果:
- 与HC相比,MSA-P显示88个上调和326个下调的DEG,在核糖体转化,免疫过程和线粒体功能方面得到丰富.
- 与HC相比,PD表现出165个上调和350个下调的DEG,与核糖体翻译,线粒体功能和无素-蛋白酶体系统有关.
- 在这两种疾病中,粉样蛋白前体蛋白被确定为关键网络枢纽;与PD相比,MSA-P显示出免疫,线粒体和神经信号基因的下调更大.
结论:
- 无论是MSA-P还是PD,都在SNpc中都有共同的转录基因变异,特别是在蛋白质合成和线粒体功能方面.
- 免疫反应和神经信号传递的独特模式使MSA-P与PD的转录学签名有所区别.
- 为了证实这些发现,需要对更大的队列进行进一步研究和功能验证.
更多相关视频
06:09Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis
Published on: February 2, 2021
5.0K
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.2K
相关概念视频
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
